64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions

Prostatic NeoplasmsCastration-Resistant

Interventions

DRUG

64Cu-SAR-BBN

DRUG

67Cu-SAR-BBN

Trial Locations (6)

Duke University, Durham

Biogenix Molecular, Miami

BAMF Health, Inc, Grand Rapids

XCancer Omaha LLC, Omaha

M D Anderson Cancer Centre, Houston

Stanford University, Stanford